Get the Stockscreener App
12.10
1.80%
-0.2061
Ars Pharmaceuticals Inc stock is traded at $12.10, with a volume of 272.52K.
It is down -1.80% in the last 24 hours and up +1.41% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$12.31
Open:
$12.2
24h Volume:
272.52K
Relative Volume:
0.21
Market Cap:
$1.16B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-25.75
EPS:
-0.47
Net Cash Flow:
$-44.23M
1W Performance:
+12.03%
1M Performance:
+1.41%
6M Performance:
-9.11%
1Y Performance:
+34.32%
1-Day Range:
$11.90
$12.50
1-Week Range:
$10.46
$12.50
52-Week Range:
$7.55
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
12.10 | 1.16B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.82 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.26 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.62 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.88 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.54 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
Neffy 1 mg Approved to Treat Severe Allergic Reactions in Younger Children - Dermatology Advisor
Scotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY) - Defense World
Scotiabank Initiates Coverage of ARS Pharmaceuticals (SPRY) with Sector Outperform Recommendation - Nasdaq
Rhumbline Advisers Buys 1,824 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Ars pharmaceuticals director Laura Shawver sells $560,445 in stock By Investing.com - Investing.com Canada
US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients - Reuters
San Diego biotech gets FDA approval for EpiPen alternative for kids - MSN
Exploring High Growth Tech Stocks in the US Market - Simply Wall St
Scotiabank sets $30 target for ARS Pharmaceuticals stock - Investing.com
Scotiabank sets $30 target for ARS Pharmaceuticals stock By Investing.com - Investing.com Canada
FDA Approves ARS Pharmaceuticals’ neffy for Type 1 Allergic Reactions in Pediatric Patients - Pharmaceutical Executive
FDA Approves Low-Dose Neffy Epinephrine Spray for Young Kids - Allergic Living
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment - Benzinga
FDA Approves neffy 1 mg for Type 1 Allergic Reactions, Including Anaphylaxis, in Children - Pharmacy Times
ARS Pharma rises on expanded US approval for allergic reaction nasal spray - TradingView
ARS Pharmaceuticals: Strategic Developments and Market Opportunities Drive Buy Rating for Neffy - TipRanks
Neffy 1mg Approved to Treat Severe Allergic Reactions in Younger Children - Monthly Prescribing Reference
ARS Pharmaceuticals announces FDA approval for neffy nasal spray - Investing.com India
ARS Pharmaceuticals announces FDA approval for neffy nasal spray By Investing.com - Investing.com South Africa
ARS Pharmaceuticals Says US FDA Approves Lower Dosage of Neffy Nasal Spray -March 05, 2025 at 05:49 pm EST - Marketscreener.com
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions - Marketscreener.com
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to - The Manila Times
US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients (March 5) - Yahoo Canada Finance
US FDA expands use of allergic reaction nasal spray in people between 15-30 kilograms - Marketscreener.com
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg - GlobeNewswire
Revolutionary Allergy Treatment: How ARS Pharma's Needle-Free Epinephrine Spray Changes Child Anaphylaxis Care - StockTitan
3 Growth Companies With High Insider Ownership Growing Earnings Up To 61% - Simply Wall St
SPRYARS Pharms Latest Stock News & Market Updates - StockTitan
ARS Pharmaceuticals’ (SPRY) “Outperform” Rating Reaffirmed at William Blair - Defense World
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences - The Manila Times
ARS Pharmaceuticals, Inc. to Host Conference Call on March 20, 2025, to Discuss Q4 and Full Year 2024 Financial Results - Nasdaq
ARS Pharmaceuticals Announces Conference Call and Webcast - GlobeNewswire
When Will ARS Pharmaceuticals Reveal Its 2024 Financial Performance? - StockTitan
Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
ARS Pharmaceuticals' (SPRY) "Outperform" Rating Reaffirmed at William Blair - MarketBeat
Allspring Global Investments Holdings LLC Increases Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Earns Outperform Rating from William Blair - Defense World
(SPRY) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Allspring Global Investments Holdings LLC Has $3.63 Million Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
Levi & Korsinsky Reminds Shareholders of an Investigation into ARS Pharmaceuticals, Inc. (SPRY) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Revolutionary Allergy Spray Gets Massive Insurance Breakthrough: Now Covered for Half of US Patients - StockTitan
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® ... - The Bakersfield Californian
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and - GlobeNewswire
Peregrine Capital Management LLC Invests $4.47 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients | Dow Theory Letters - Financial Content
ARS Pharmaceuticals Presents Data On Neffy Epinephrine Nasal Spray At 2025 AAAAI Meeting - Nasdaq
ARS Pharmaceuticals to Showcase Innovation and Present Data - GlobeNewswire
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) ... - The Bakersfield Californian
Revolutionary Needle-Free Allergy Treatment Shows Superior Results: Clinical Data Reveals Game-Changing Efficacy - StockTitan
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):